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Surgery for lymph node metastases of
medullary thyroid carcinoma
Linda X Jin1 & Jeffrey F Moley*,2,3

Practice points
●●

No known effective systemic therapy exists for medullary thyroid carcinoma (MTC), and surgery remains the first-line
treatment for curative therapy.

●●

Lymph node involvement in MTC affects prognosis, and nodal status is incorporated into the American Joint Committee
on Cancer MTC staging classification, in addition to tumor size, invasion and distant metastases.

●●

Hereditary medullary thyroid cancer syndromes include MEN 2A, MEN 2B and familial MTC and are associated with
germline mutations in the RET proto-oncogene on chromosome 10q11.2. Knowledge of the specific RET mutation allows
clinicians to stratify patients in risk groups based on age of onset and aggressiveness of MTC.

●●

In patients with palpable disease but without evidence of local invasion, cervical node metastases or distant metastases,
total thyroidectomy accompanied by a central node dissection (level VI nodes) is the appropriate primary treatment.

●●

Systematic, compartment-oriented approach to the removal of nodal tissue improves survival rates and reduces
recurrence rates, and should be performed instead of procedures with removal of only grossly involved nodes.

●●

The majority of patients with palpable MTC have regional metastases at the time of diagnosis, for which surgical clearance
is the only effective therapy.

●●

Ipsilateral neck dissection, also called ‘functional’ or ‘modified radical’ neck dissection, in which all or portions of levels II,
III, IV and V nodes are removed, should be considered in all patients with clinically evident MTC.

●●

The burden of lymph node metastasis in the central compartment can help predict lateral compartment involvement.

●●

In MEN 2A and familial MTC with high-risk mutations, an ipsilateral or bilateral central neck dissection (level VI) should be
performed in the presence of palpable or radiologically identifiable lymphadenopathy or elevation of calcitonin level >40
pg/ml. Patients with low-risk mutations (level I) with calcitonin level <40 pg/ml and no evidence of nodal disease should
receive a total thyroidectomy, leaving the parathyroid in situ.

●●

Patients with MEN 2B should receive thyroidectomy at infancy, as MTC is often present at birth, with additional central
neck dissection if the calcitonin level is elevated.

●●

All patients should be followed with calcitonin levels measured postoperatively and semiannually thereafter.

●●

Reoperation should be considered for patients with elevated calcitonin levels in the setting of an inadequate initial
operation, imaging evidence of recurrent or persistent local disease, or for threat of compression or invasion of the
trachea or major vessels.

●●

A significant reduction in stimulated calcitonin levels after reoperation can be achieved through a thorough
microdissection, which involves dissection of all lymph node and fatty tissue of the central and lateral zones of the neck,
both recurrent nerves, as well as nodes of the lateral neck.
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Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy of the thyroid C
cells, and can commonly spread to cervical and mediastinal lymph nodes. MTC cells do
not concentrate radioactive iodine and are not sensitive to hormonal manipulation, and
therefore surgery is the only effective option for curative therapy, reduction in tumor burden
or effective palliation. In patients undergoing preventative operations for hereditary MTC,
central lymph node dissection should be considered if the calcitonin level is above 40 pg/ml.
Systematic removal of at-risk or involved lymph node compartments should be performed
in all patients with palpable primary tumors and recurrent disease, and a ‘berry-picking’
approach should be avoided.
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Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy of the calcitonin producing thyroid C cells, also known as parafollicular cells. Parafollicular C cells are of neural
crest derivation, and are dispersed throughout
the normal thyroid gland. C cells secrete calcitonin, a hormone involved in calcium metabolism. Elevated calcitonin level is a sensitive and
specific marker for the presence of MTC. It is
valuable in both screening and follow-up of
patients with MTC. MTC accounts for 4%
of all thyroid cancers, and displays a variety
of clinical behaviors ranging from indolent to
aggressive [1,2] .
MTC has several distinctive features. First,
MTC may be sporadic (75% of cases) or hereditary (25% of cases), occurring in all patients
with multiple endocrine neoplasia type 2
(MEN 2) syndromes [3] . Sporadic cases of
MTC usually present with a palpable thyroid
mass, while hereditary cases may be detected
and treated on the basis of genetic testing once
the syndrome is diagnosed in a family. Second,
although MTC is more aggressive than differentiated thyroid carcinoma, it is still an indolent
malignancy, with reported 10-year survival rates
from 69 to 89% [1,4–5] . Finally, unlike differentiated thyroid cancer, no known effective systemic
therapy exists for MTC, although recent trials
with small molecule inhibitors are promising.
MTC cells do not concentrate radioactive iodine
and are not sensitive to the manipulation of
thyroid-stimulating hormone. All these features
influence the choice for therapy in patients with
MTC. While newly approved targeted molecular therapies offer wider treatment options for
symptomatic, locally advanced, metastatic progressive unresectable MTC, surgery remains the
first-line treatment for curative therapy.
Primary MTC tumors may invade adjacent
structures, including the larynx, trachea, recurrent laryngeal nerve and esophagus. In familial
forms, tumors are usually bilateral and multifocal. Once the primary tumor is established,
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metastasis to regional lymph nodes occurs earlier than in differentiated thyroid cancer [6,7] .
Nodes in the central compartment (levels VI
and VII) are most often involved, followed by
levels II–V on the ipsilateral, and frequently
the contralateral side (Figure 1) . Involved lymph
nodes seen on preoperative ultrasound may
appear enlarged, with lack of a fatty hilum and
microcalcifications, as well as abnormal blood
flow pattern (Figure 2) . We do not routinely use
fine needle aspiration to evaluate lymph nodes
preoperatively as abnormal appearance on ultrasound is already an indication for intraoperative removal. Metastatic spread to the upper and
anterior mediastinum may also be observed.
Hematogenous spread occurs variably in the
course of MTC, generally to the liver, lungs and
bone. Distant metastases often occur in a fine
miliary pattern that is not well visualized on CT
scans or other anatomic imaging.
Lymph node involvement in MTC affects
prognosis, and nodal status is incorporated into
the American Joint Committee on Cancer MTC
staging classification, in addition to tumor size,
invasion and distant metastases. In several studies, 10-year cause-specific survival was most
inf luenced by age, stage and postoperative
basal calcitonin levels [5,9] . This was confirmed
in a recent review, which again showed that the
most sensitive predictors of survival were age
at diagnosis and tumor stage [10] . In this series,
differences in survival time were correlated with
biochemical and radiographic remission. In
those who did not, 10-year survival was slightly
reduced to 73%. These observations confirm
the indolent nature of the disease and suggest
the benefit of therapeutic interventions that
keep tumor burden at a minimum, including
reoperative surgery when technically possible.
Hereditary medullary thyroid cancer
Hereditary MTC syndromes include MEN
2A, MEN 2B and familial MTC (FMTC).
These syndromes are associated with germline
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Figure 1. Lymph node dissection during surgery for medullary thyroid carcinoma. (A) Lymph node groups in the neck. (B) Specimen
from a patient following central and bilateral neck dissection. Level II nodes are from the high jugular nodes; level III, mid-jugular nodes;
level IV, low jugular nodes; level V, posterior triangle nodes; level VI, paratracheal nodes; level VII, superior mediastinal nodes.
Reproduced with permission from [8].

mutations in the RET proto-oncogene on
chromosome 10q11.2. [11–13] This gene encodes
a tyrosine kinase receptor protein involved
in growth, differentiation and migration of
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developing tissues. In MEN 2A and FMTC,
mutations within codons specifying cysteine
residues in the extracellular ligand-binding
domain of the RET gene product are most
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commonly found. In MEN 2B, a mutation
is found in the intracellular tyrosine kinase
domain. Changes in protein structure and
function that result from these mutations predispose to neoplasia by a dominant oncogenic
mechanism [14] .
Each of the hereditary MTC syndromes
has unique associated endocrine abnormalities, but all have near-complete penetrance of
MTC. Progression from C-cell hyperplasia to
intrathyroidal MTC with eventual lymphatic
and metastatic spread is age dependent and
related to expression of specific RET mutation
phenotypes [15,16] . Knowledge of the specific
RET mutation allows clinicians to stratify
patients in risk groups based on age of onset
and aggressiveness of MTC: highest (level III),
high (level II) and low (level I) level risk [17] .
MEN 2A is characterized by multifocal,
bilateral MTC, pheochromocytoma (42%
penetrance) and hyperparathyroidism (10 to
30% penetrance). It is associated with RET
mutations affecting extracellular cysteine residues [11–12,14,18–20] . Cutaneous lichens amyloidosis and Hirschsprung’s disease has also been
described in patients with MEN 2A. MEN 2A
has a variable course based on codon mutation.
Mutations in codon 611, 618, 620 and 634
pose a level II risk. Patients with mutations in
the 634 codon have an increasing, cumulative
age-related risk of lymph node metastasis, starting from the mid-teens and reaching a >40%
cumulative risk by the age of 20. MEN 2A with
mutations in codons 768, 790, 804 or 891 are
less aggressive (level I risk) and often present in
the second or third decade of life.

Figure 2. Metastatic sporadic medullary
thyroid cancer to central lymph nodes anterior
to the trachea. The nodes are enlarged, there is
lack of a fatty hilum and microcalcifications, and
there is an abnormal blood flow pattern.
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FMTC represents a clinical variant of MEN
2A in which only MTC is seen. FMTC is caused
by the same genetic mutations as MEN 2A as
well as by less common mutations in the intracellular portion of the gene product [11,15–16,18].
Commonly associated mutations occur in
codons 609, 611, 618 and 620 in exon 10; codon
768 in exon 13 and codon 804 in exon 14 [17,21] .
Generally, FMTC-related mutations are least
aggressive (level I risk).
MEN 2B is characterized by MTC with onset
at a very young age, pheochromocytoma (40%
penetrance), multiple mucosal neuromas, ganglioneuromatosis of the GI tract and megacolon. MEN 2B is most commonly caused by a
methionine to threonine mutation in codon 918
of the catalytic domain of tyrosine kinase. MTC
in the setting of MEN 2B is typically the most
aggressive (level III risk), with invasive carcinoma in the first year of life and early lymph
node metastasis.
The surgical approach in older RET mutation carriers should be individualized based
on calcitonin level, presence of palpable disease, imaging results, RET mutation and
family history.
Initial surgical treatment of clinically
evident disease
The surgical treatment of MTC is guided by
several key principles. First, the biology and
behavior of MTC is very different from those of
differentiated thyroid cancer. MTC cells do not
take up iodine and radioactive iodine therapy is
ineffective. Unlike differentiated thyroid cancer,
MTC does not respond to thyroid suppression
using levothyroxine; thus surgery is the only
effective therapeutic modality. Second, MTC
is multicentric in 90% of patients with hereditary forms of the disease and in 20% of patients
with the sporadic form. Third, nodal metastases are present in more than 70% of patients
with palpable disease [22,23] . Last, the ability to
measure postoperative stimulated calcitonin levels allows the adequacy of surgical extirpation
to be assessed.
In patients with palpable disease but without
evidence of local invasion, cervical node metastases or distant metastases, total thyroidectomy
accompanied by a central node dissection (level
VI nodes) are the appropriate primary treatment (Figure 3) [3] . Systematic, compartmentoriented approach to removal of nodal tissue was
reported to improve survival rates and reduce
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Figure 3. Lymph node metastases in medullary thyroid carcinoma. (A) Computerized tomography showing left-sided medullary
thyroid cancer; (B) intraoperative photo showing the thyroidecomy and central neck dissection bed; (C) operative specimen after
thyroidectomy and central neck dissection.

recurrence rates when retrospectively compared
with procedures with removal of only grossly
involved nodes (‘berry picking’) [24] . During
this dissection, all thyroid and nodal tissue are
removed from the level of the hyoid bone to the
innominate vessels. All four parathyroid glands
should be identified if possible. Central nodal
tissue on the anterior surface of the trachea is
removed, exposing the superior surface of the
innominate vein behind the sternal notch. Fatty
and nodal tissue between the carotid sheaths
and the trachea should be removed, including
paratracheal nodes along the recurrent nerves.
On the right, the junction of the innominate
and right carotid arteries is exposed, and on the
left, nodal tissue is removed to a comparable
level behind the head of the left clavicle.
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MTC tumors sometimes involve the recurrent laryngeal nerve. If the nerve is functioning
on preoperative laryngoscopy, attempts should
be made to preserve it, though this is sometimes
not possible. In cases where the nerve is not
functioning at the end of the case, special care
must be taken to preserve the contralateral normal nerve. If the patient has stridor postoperatively due to bilateral nerve dysfunction (which
is not uncommon if one nerve is removed, and
the other manipulated during thyroidectomy),
airway patency can be achieved by one of several methods. These include keeping the patient
intubated until the noninjured nerve recovers,
using steroids and helium–oxygen mixtures to
combat airway obstruction, and surgical lateralization of the nonfunctioning vocal cord on
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the side of the resected nerve for effective temporary opening of the airway. It is not advisable
to place a tracheostomy in a field where central nodes have just been cleared down into the
upper mediastinum, as there will be no tissue
between the innominate vessels and the tracheostomy. This can lead to leaks, mediastinitis and
innominate blowout. If a tracheostomy must be
done, a vascularized muscle pedicle should be
placed between the tracheal opening and the
innominate vessels to protect them.
Controversy exists over the optimal management of the parathyroid glands in operations for
MTC. Some surgeons prefer to leave the parathyroid glands in situ, ensuring that the vascular pedicle is preserved [25,26] . Others routinely
perform four-gland parathyroidectomy with
autotransplantation and argue that adequate
central node dissection is not possible if the parathyroid glands are left in place [27] . Although
various approaches exist, it is important to
emphasize that the individual surgeon should do
whichever procedure he/she is most comfortable
with to achieve a universal goal of preserving
parathyroid function. Our approach is to resect
the two parathyroids ipsilateral to the primary
tumor and the contralateral inferior parathyroid,
leaving the contralateral superior parathyroid
intact on a vascular pedicle. Removed parathyroids are then minced into 1 × 3 mm fragments
and transplanted into individual muscle pockets
with two to three fragments per pocket. The
pockets are then closed with a 4–0 suture [28] .
Choice of muscle for transplantation is based on
disease process. We use the sternocleidomastoid
muscle in patients with sporadic MTC, FMTC
and MEN 2B and the nondominant forearm in
patients with MEN 2A, due to the risk of developing graft-dependent hyperparathyroidism. In
MEN 2A patients who have concurrent hyperparathyroidism at the time of operation, a fourgland parathyroidectomy should be performed,
with at least 100 mg of parathyroid tissue being
transplanted. All residual tissue should be viably
frozen [29] . The parathyroid autografts generally
function well within 4–6 weeks, at which time
calcium supplementation can be stopped.
●●Management of regional lymph nodes in

clinically evident disease

Regional nodal metastases are present in the
majority of patients with palpable MTC.
Because these tumors do not take up iodine,
nodal metastases cannot be ablated with
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radioactive iodine. Surgical clearance is the only
effective strategy for eliminating these metastases [24,30–31] . Ipsilateral neck dissection, also
called ‘functional’ or ‘modified radical’ neck
dissection, in which all or portions of levels
II, III, IV and V nodes are removed, should be
considered in all patients with clinically evident
MTC and especially in patients suspected to
have locally advanced disease. At our institution,
we evaluated the incidence and pattern of nodal
metastases in patients with palpable MTC [22] .
In this series, 73 patients with palpable MTC
underwent thyroidectomy with concurrent or
delayed central and bilateral cervical node dissection. The number and location of lymph
node metastases in the central (levels VI and
VII) and lateral (levels II–V) nodal groups were
noted and correlated with the size and location
of the primary tumor. In patients with unilateral
intrathyroidal tumors, nodal metastases were
present in 81% in central level VI, in 81% in
ipsilateral levels II–V and in 44% in contralateral levels II–V nodal groups. In patients with
bilateral intrathyroidal tumors, nodal metastases were present in 78% of central level VI nodal
groups, in 71% of level II through V nodes ipsilateral to the largest intrathyroidal tumor and in
49% of level II through V nodes contralateral
to the largest intrathyroidal tumor. This is an
alarmingly high incidence of nodal involvement.
In this same series, we found that intraoperative
nodal assessment by the surgeon had a low sensitivity (64%) and specificity (71%) for detecting positive nodes [22] . Therefore, reliance on
intraoperative assessment and a ‘berry picking’
strategy may miss clinically involved nodes up to
a third of the time. If central nodes are positive
on frozen section, it is an indication for further
dissection of lateral nodes. However, it is not our
practice to routinely use intraoperative frozen
section and rely more on preoperative imaging
characteristics and preoperative calcitonin as
discussed above.
The burden of lymph node metastasis in
the central compartment can help predict lateral compartment involvement. In one retrospective analysis, the presence of zero positive
central nodes correlated with a 10% risk of
metastatic involvement of ipsilateral level II–V
nodes. However, the risk of lateral compartment
involvement increased to 77% with one to three
positive central nodes, and to 98% with four or
more positive central nodes [32] . Contralateral
level II–V metastases were observed in 4.9%
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of cases when zero central nodes were positive,
in 28% when one to nine central nodes were
positive and in 77% of cases when ten or more
central nodes were positive [32] . Therefore, the
decision to perform lateral neck dissection is
influenced by the extent of central compartment nodal involvement as well as preoperative
imaging assessment. If extensive central node
metastases are present, even with negative preoperative imaging, serious consideration should
be given to performing an ipsilateral functional
neck dissection given the high likelihood of
microscopic nodal involvement. A recent study
has also showed that in patients with preoperative basal calcitonin levels <200 pg/ml, the risk
of contralateral neck involvement was low, but
in patients who crossed that threshold, the risk
of contralateral neck involvement increased
significantly [33] . These data suggest that in
addition to central compartment lymph node
burden, the level of basal preoperative calcitonin
may also help inform the decision of whether to
perform a bilateral lateral neck dissection.
Management of lymph nodes during
preventative surgery for hereditary MTC
The goal of curative therapy for patients with
hereditary MTC is complete surgical resection
prior to malignant transformation or spread
beyond the thyroid gland, regardless of calcitonin levels. RET mutation carriers often
harbor foci of MTC in the thyroid gland even
when stimulated calcitonin levels are normal [34–36] . A recent study in pediatric patients
with hereditary MTC compared nine patients
who had age appropriate thyroidectomy with 19
patients who had thyroidectomy at a later age
according to North American Neuroendocrine
Tumor Society guidelines. Patients who had
age appropriate thyroidectomy were cured
with no disease recurrence, while patients who
had thyroidectomy past the recommended age
had a 42% recurrence rate [37] . However, other
groups have suggested that following patients
with known hereditary disease using stimulated calcitonin levels may also be a safe way to
individualize timing of surgery [38] .
In MEN 2A and FMTC, the timing of
thyroidectomy remains controversial. Highrisk (level II) mutations associated with MEN
2A (codons 611, 618, 620, 634) should have
thyroidectomy at or before age 5 or 6 years.
An ipsilateral or bilateral central neck dissection (level VI) is additionally recommended
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in the presence of palpable or radiologically
identifiable lymphadenopathy or elevation of
calcitonin level >40 pg/ml. However, patients
with low-risk mutations (level I) associated with
MEN 2A and FMTC have extremely low risk
of nodal metastasis in patients under the age
of 8, or if the calcitonin level is <40 pg/ml [27] .
For this reason, it is our practice to perform
a total thyroidectomy, leaving the parathyroid
in situ if the calcitonin level is <40 pg/ml and
there is no evidence of nodal disease. Patients
with elevated calcitonin level, a thyroid nodule
over 5 mm in size (at any age), or with radiographic evidence of lymph node metastasis
should undergo total thyroidectomy with central node dissection. An ipsilateral dissection
of levels II–V should also be considered if the
calcitonin is >40 pg/ml, and certainly should
be done if there is ultrasound evidence of nodal
metastases [33] . This operation should only be
performed by surgeons familiar with thyroid
and parathyroid operations in children [36] . We
reported long-term follow-up results from a
series of 50 pediatric patients with MEN 2A following thyroidectomy, central node dissection
and total parathyroidectomy with autotransplantation [36] . Long-term disease control was
excellent and long-term parathyroid function
was normal (no supplementation) in 93% of
patients. Other groups reported good results
with selective removal of lymph nodes and
parathyroids in young at-risk patients [34,35] .
Highest risk (level III) mutations, associated
with MEN 2B require a different approach. In
these patients, thyroidectomy should be performed in infancy, as MTC is often already
established at birth. Central neck dissection
should be performed if the calcitonin level is
elevated. This requires that the surgeon has
identified and preserved the parathyroids,
either by autotransplantation or preservation
on an intact vascular pedicle. The consequences
of hypoparathyroidism in an infant are disastrous, and all possible steps must be taken to
avoid this. The parathyroid glands at this age
are extremely small and translucent, and often
obscured by prominent cervical thymic tissue,
making identification difficult for even the
most experienced parathyroid surgeon. If the
surgeon is unable to identify and preserve the
parathyroids, a central neck dissection should
be deferred until a later age or a surgeon with
more extensive experience is available. For
both MEN 2A and 2B cases with concurrent
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pheochromocytoma, the pheochromocytoma
should be treated first.
Management of recurrent or persistent
disease
After primary surgery for MTC, persistent
or recurrent elevation of the basal or stimulated calcitonin levels indicates the presence
of residual or recurrent tumor. Patients with
normal calcitonin levels following MTC surgery have achieved ‘biochemical cure’. Patients
with mildly elevated but stable serum calcitonin
levels (<150 pg/ml) following adequate primary
surgery have biochemical evidence of residual
disease. MTC can be a very indolent disease,
and many patients with persistently high levels
of calcitonin after thyroidectomy and node dissection continue to do well without evidence
of disease for many years. However, patients
with more aggressive forms of MTC can have
a rapidly progressive course. One series from
Mayo Clinic reported a 66% mortality rate in
node-positive patients with hereditary MTC
after a median follow-up of 15.7 years [39,40] .
Therefore, all patients should be followed with
calcitonin levels measured postoperatively and
semiannually thereafter.
Reoperation should be considered for patients
with elevated calcitonin levels in the setting of
an inadequate initial operation, imaging evidence of recurrent or persistent local disease,
or for threat of compression or invasion of the
trachea or major vessels. Reoperative surgery
for locoregional disease, in experienced hands,
can achieve long-term control and biochemical cure in up to a third of patients [41–44] .
Metastatic workup is necessary before proceeding with neck reoperation with curative
intent. Palliative tumor debulking procedures
are helpful in patients who have pain, systemic
symptoms of flushing and diarrhea, or those
with tumor that threatens to cause airway or
vascular compromise.
A significant reduction in stimulated calcitonin levels after reoperation can be achieved
through a thorough microdissection. This
involves a meticulous dissection of all lymph
node and fatty tissue of the central and lateral
zones of the neck, including the thyroid bed,
both recurrent nerves, and nodes of the lateral
neck, extending from the level of the mastoid
process down to the innominate vein and subclavian arteries and out laterally to the level of the
spinal accessory nerve. In some cases, a median
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sternotomy and resection of upper mediastinal
nodes may also be necessary. Previously, we
reported two series of reoperations for MTC.
In the first series, 37 reoperations were done in
32 patients. In 28% of patients, calcitonin was
reduced to undetectable levels following reoperation, and in an additional 42% of patients, calcitonin levels were decreased by 40% or more [45] .
In the second series, we sought to improve our
results through better selection of patients most
likely to benefit from reoperation. This was
achieved by obtaining a systematic metastatic
workup prior to reoperation, including routine
staging laparoscopy [46,47] . In 45 patients who
had reoperation with curative intent, the mean
decrease in postoperative-stimulated calcitonin
level was 73%, and in 86% of patients, postoperative-stimulated calcitonin levels were within
the normal range or lower. More recently, we
reported the long-term follow-up results after
reoperation. Of the 56 patients with 8–10-year
follow-up data, 25 (46%) had normal or stable
basal calcitonin levels and no radiologic evidence of disease recurrence [40,44] . These results
support the use of a systematic microdissection
approach to reoperation in patients with a persistent or recurrent elevation of calcitonin levels
after surgery for MTC.
Re-exploration of the neck carries a higher
risk of complications, including thoracic duct
leak, injury to the recurrent laryngeal nerve
and hypoparathyroidism. Use of intraoperative
nerve monitoring devices and bipolar cautery in
redo surgery is helpful. In children, central neck
reoperations are especially dangerous due to the
small size of the parathyroids. These should be
avoided unless bulky central disease threatening the airway or the great vessels makes the
operation absolutely necessary. A ‘back-door’
or lateral approach helps to facilitate redo central neck dissection. This operation has been
described in detail by our group elsewhere. In
this procedure, the strap muscles are mobilized
off the carotid artery and the space between
the carotid and the trachea is entered through
a previously undissected tissue plane [48–50] . As
always, it is imperative to identify the recurrent
laryngeal nerve and parathyroids to ensure safe
removal of recurrent or residual central disease
and lymph nodes [48–50] . Preoperative imaging, clinically palpable nodes and presence of
central compartment lymph node disease
should be used as indications for lateral neck
dissections (levels II–V).
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Conclusion
The propensity for MTC to metastasize to cervical lymph nodes is a defining feature of this
disease that informs surgical management in all
clinical settings: prophylactic surgery in RET
mutation carriers, primary operations for established tumors, reoperations for persistent and
recurrent disease, and palliative procedures for
symptomatic tumors. Eradication of involved
nodes can result in long-term cure or disease
control. A working knowledge of cervical lymph
node anatomy and the natural history of MTC
spread within these nodal groups is important
to surgeons managing these patients. The parathyroid glands are intimately related to the central nodes. Careful, correct management of the
parathyroid glands in these situations will minimize the risk for hypoparathyroidism, which
especially must be avoided in young children.
Future perspective
The propensity for MTC to metastasize to cervical lymph nodes is a defining feature of this
disease that informs surgical management in all
clinical settings: prophylactic surgery in RET
mutation carriers, primary operations for established tumors, reoperations for persistent and
recurrent disease, and palliative procedures for
symptomatic tumors. Eradication of involved
nodes can result in long-term cure or disease
control and is currently the treatment option
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